31211282|t|The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents.
31211282|a|This study was designed with the rational aim of discussing the emerging antidepressant agents that are likely to bring positive landmark, tremendous improvement and significant impact to the management of patients with depression disorders. It also elaborates on the Agomelatine paradox vis-a-vis the other novel antidepressant agents. The emerging antidepressants are: selective monoamine oxidase inhibitors (MAOIs) such as bifemelane, pirlindole, toloxatone, selegiline, rasagiline and safinamide; serotonin-norepinephrine reuptake inhibitors (SNRIs) such as ansofaxine, nefopam and levomilnacipran; norepinephrine reuptake inhibitors (NRIs) such as Reboxetine, viloxazine, teniloxazine (also known as sulfoxazine or sufoxazine), and atomoxetine; Vilazodone (a serotonin 5-HT1A autoreceptor partial agonist with serotonin reuptake inhibition [SPARI]); Vortioxetine (a serotonin receptors antagonist with serotonin reuptake inhibition [SARI]); atypical antipsychotics such as olanzapine, quetiapine, risperidone, lurasidone, aripiprazole and brexpiprazole; N-methyl-d-aspartate (NMDA)-glutamatergic neurotransmission system blockers such as ketamine, CP-101,606 (traxoprodil), GLYX-13 (rapastinel), NRX-1074 (Apimostinel) and Riluzole. While Agomelatine (a melatonergic MT 1 and MT 2 receptors agonist and a selective serotonergic 5-HT 2B and 5-HT 2C receptors antagonist [MASSA]) remains a paradoxical agent that doesn't fit into any of the currently available classes of antidepressant agents and its pharmacological properties also deemed it unfit and inappropriate to be classified into another separate novel class of antidepressants contrary to the reports published in previous reference literatures. Lastly, this review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders.
31211282	55	66	Agomelatine	Chemical	MESH:C084711
31211282	308	316	patients	Species	9606
31211282	322	342	depression disorders	Disease	MESH:D003866
31211282	370	381	Agomelatine	Chemical	MESH:C084711
31211282	528	538	bifemelane	Chemical	MESH:C031906
31211282	540	550	pirlindole	Chemical	MESH:C009830
31211282	552	562	toloxatone	Chemical	MESH:C010798
31211282	564	574	selegiline	Chemical	MESH:D012642
31211282	576	586	rasagiline	Chemical	MESH:C031967
31211282	591	601	safinamide	Chemical	MESH:C092797
31211282	603	612	serotonin	Chemical	MESH:D012701
31211282	613	647	norepinephrine reuptake inhibitors	Chemical	-
31211282	649	654	SNRIs	Chemical	-
31211282	664	674	ansofaxine	Chemical	-
31211282	676	683	nefopam	Chemical	MESH:D009340
31211282	688	703	levomilnacipran	Chemical	MESH:D000078862
31211282	705	739	norepinephrine reuptake inhibitors	Chemical	-
31211282	741	745	NRIs	Chemical	-
31211282	755	765	Reboxetine	Chemical	MESH:D000077593
31211282	767	777	viloxazine	Chemical	MESH:D014745
31211282	779	791	teniloxazine	Chemical	MESH:C045330
31211282	807	818	sulfoxazine	Chemical	-
31211282	822	832	sufoxazine	Chemical	MESH:C045330
31211282	839	850	atomoxetine	Chemical	MESH:D000069445
31211282	852	862	Vilazodone	Chemical	MESH:D000069503
31211282	866	875	serotonin	Chemical	MESH:D012701
31211282	876	882	5-HT1A	Gene	3350
31211282	917	926	serotonin	Chemical	MESH:D012701
31211282	957	969	Vortioxetine	Chemical	MESH:D000078784
31211282	1009	1018	serotonin	Chemical	MESH:D012701
31211282	1080	1090	olanzapine	Chemical	MESH:D000077152
31211282	1092	1102	quetiapine	Chemical	MESH:D000069348
31211282	1104	1115	risperidone	Chemical	MESH:D018967
31211282	1117	1127	lurasidone	Chemical	MESH:D000069056
31211282	1129	1141	aripiprazole	Chemical	MESH:D000068180
31211282	1146	1159	brexpiprazole	Chemical	MESH:C000591922
31211282	1161	1181	N-methyl-d-aspartate	Chemical	MESH:D016202
31211282	1183	1187	NMDA	Chemical	MESH:D016202
31211282	1245	1253	ketamine	Chemical	-
31211282	1255	1265	CP-101,606	Chemical	MESH:C095106
31211282	1267	1278	traxoprodil	Chemical	MESH:C095106
31211282	1281	1288	GLYX-13	Chemical	MESH:C507283
31211282	1290	1300	rapastinel	Chemical	MESH:C507283
31211282	1303	1311	NRX-1074	Chemical	-
31211282	1313	1324	Apimostinel	Chemical	-
31211282	1330	1338	Riluzole	Chemical	MESH:D019782
31211282	1346	1357	Agomelatine	Chemical	MESH:C084711
31211282	1361	1397	melatonergic MT 1 and MT 2 receptors	Chemical	-
31211282	1422	1434	serotonergic	Chemical	-
31211282	1477	1482	MASSA	Chemical	-
31211282	1910	1914	NMDA	Chemical	MESH:D016202
31211282	2067	2087	depression disorders	Disease	MESH:D003866
31211282	Negative_Correlation	MESH:D016202	MESH:D019782
31211282	Positive_Correlation	MESH:D012701	3350
31211282	Negative_Correlation	MESH:C095106	MESH:D016202
31211282	Negative_Correlation	MESH:C507283	MESH:D016202
31211282	Positive_Correlation	MESH:D000069503	MESH:D012701

